Humacyte, Inc. (HUMA) vs ImmuCell Corporation (ICCC)
A side-by-side comparison of Humacyte, Inc. and ImmuCell Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HUMA
Humacyte, Inc.
$0.51HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
ICCC
ImmuCell Corporation
$9.85HealthcareDelayed quote: Oct 6, 2026, 11:00 AM EDT
Total return — HUMA vs ICCC
growth of $100 · dividends reinvested · last 6yHUMA -94.8% (-39.0%/yr)ICCC +70.8% (+9.3%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
HUMA ICCC
HUMA vs ICCC: by the numbers
- •ICCC is the larger company ($89M vs $85M market cap).
- •ICCC is profitable (2.57% net margin) while HUMA runs a net loss (-4560.82%).
- •ICCC grew revenue faster over the past five years (13.74% vs 2.41% CAGR).
Metrics side by side
Valuation
| Metric | HUMA | ICCC |
|---|---|---|
| P/E ratio | N/A | 116.43 |
| P/S ratio | 40.18 | 2.90 |
| P/B ratio | 2.73 | 2.84 |
| EV / EBITDA | N/A | 14.83 |
| FCF yield | N/A | 4.73% |
Profitability
| Metric | HUMA | ICCC |
|---|---|---|
| Gross margin | -736.46% | 40.32% |
| Operating margin | -5271.69% | 12.60% |
| Net margin | -4560.82% | 2.57% |
| ROE | -309.44% | 2.51% |
| ROIC | -90.27% | 8.16% |
Growth (annualized)
| Metric | HUMA | ICCC |
|---|---|---|
| Revenue CAGR (5Y) | 2.41% | 13.74% |
| Total return CAGR (5Y) | -45.73% | 0.65% |
Frequently asked
- Which has grown faster, HUMA or ICCC?
- Over the past five years, ICCC grew revenue faster — HUMA at a 2.41% CAGR versus ICCC at 13.74%.
- Is HUMA or ICCC more profitable?
- ICCC runs the higher net margin — HUMA at -4560.82% versus ICCC at 2.57%.
- How have HUMA and ICCC total returns compared?
- Over the past 5 years, HUMA delivered -45.73% and ICCC delivered 0.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmuCell P/E ratioHumacyte ROEImmuCell ROEHumacyte operating marginImmuCell operating marginHumacyte revenue growthImmuCell revenue growthHumacyte free cash flowImmuCell free cash flow
Humacyte & ImmuCell appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.